PIT565

BIOLOGICAL3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin Lymphoma (B-NHL)Rheumatoid ArthritisSystemic Lupus Erythematosus, SLE

Phase 1

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Active, not recruitingNCT05397496

Novartis PharmaceuticalsB-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin Lymphoma (B-NHL)

Start: 2022-10-03End: 2027-01-04Updated: 2026-07-28

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Active, not recruitingNCT06335979

Novartis PharmaceuticalsSystemic Lupus Erythematosus, SLE

Start: 2024-10-08End: 2027-11-17Target: 54Updated: 2026-06-30

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

Active, not recruitingNCT07029555

Novartis PharmaceuticalsRheumatoid Arthritis

Start: 2025-06-12End: 2028-05-16Target: 57Updated: 2026-06-30

Related Papers

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood2023-11-023 citations

PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

Blood2022-11-1519 citations